Trehalose for Health & Longevity - Quick Reference Sheet

Trehalose for Health & Longevity

Created on 08/12/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 Audit

Trehalose is a natural sugar that stabilizes proteins and switches on the cell's recycling machinery in the laboratory, but the gut splits swallowed trehalose into ordinary glucose before most of it acts. As eye drops it reliably improves dry eye. Small oral doses raise blood sugar more gently than table sugar. The evidence is thin and conflicted. (Full Review)

Protocol

Metabolic protocol
3.3–10 g/day
Powder replacing an equivalent amount of dietary sugar, for 12 weeks before assessing effect
Ocular protocol
3% drops, 3–4× daily
With or without 0.15% sodium hyaluronate; the only route with high-quality efficacy evidence
Best time of day
With meals
Split across meals above roughly 10 g, keeping each dose below the intestinal enzyme's capacity
Time to effect
Dry eye relief
Days to 2 weeks
Topical use
Metabolic effects
12 weeks
Measured only after 12 weeks of daily intake
Vascular effects
12 weeks
Required a full 12-week course

Benefits

Contraindications
  • Diagnosed trehalase deficiency or a history of severe symptoms after mushrooms
  • Active or recent Clostridioides difficile infection (within 90 days) or current broad-spectrum antibiotics
  • Poorly controlled type 2 diabetes (HbA1c above 8%), at the higher dose ranges
  • Diarrhea-predominant irritable bowel syndrome or active inflammatory bowel disease
Key Interactions
  • Glucose-lowering medications (metformin, sulfonylureas, insulin, sodium-glucose cotransporter-2 inhibitors such as empagliflozin)
  • Osmotic laxatives and stool softeners (lactulose, polyethylene glycol, magnesium hydroxide)
  • Sugar alcohols and poorly absorbed sweeteners (sorbitol, xylitol, erythritol, maltitol, inulin)
  • Supplements with additive glucose-lowering effects (berberine, alpha-lipoic acid, chromium picolinate, cinnamon extract)
  • Other autophagy-directed interventions (rapamycin, spermidine, prolonged fasting)

Risk & Side Effects

  • High: Dose-dependent gastrointestinal intolerance; glucose and calorie load
  • Medium: Enhanced growth of epidemic gut-bacterial lineages; adverse events with intravenous trehalose
  • Low: Fermentation by oral bacteria
  • Speculative: Bladder overactivity; blockade rather than induction of cellular recycling

Monitoring

Marker Target Why
Fasting glucose 75–85 mg/dL Detects whether the added sugar load is worsening baseline glycemia
2-hour post-load glucose Below 120 mg/dL The endpoint that improved in the human trials; the primary efficacy measure
Glycated hemoglobin (HbA1c) 4.8–5.3% Confirms that short-term glucose changes translate into an average benefit, not just a shifted curve
Triglycerides Below 80 mg/dL Rises early when surplus carbohydrate is being converted to fat
Body weight and waist circumference Stable within 1 kg of baseline The most sensitive early sign that trehalose is being added rather than substituted
High-sensitivity C-reactive protein (hs-CRP) Below 1.0 mg/L General inflammation marker; the vascular trial found no change, so a rise argues against continuing
Dry eye symptom score Improvement of 8 points or more Tracks the one benefit with high-quality evidence, for topical users

Cadence: Weight weekly during titration, then the full metabolic panel at 12 weeks and, where intake continues, every 6 months thereafter

Qualitative Assessment

  • Bloating, flatulence and stool consistency in the days after each dose increase
  • Post-meal energy stability, and absence of the mid-afternoon slump
  • Eye comfort late in the day and tolerance of screen work, for topical users
  • Perceived endurance and recovery during long training sessions